T-cell acute lymphoblastic leukemia in patients 1–45 years treated with the pediatric NOPHO ALL2008 protocol

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

T-cell acute lymphoblastic leukemia in patients 1–45 years treated with the pediatric NOPHO ALL2008 protocol. / Quist-Paulsen, P.; Toft, N.; Heyman, M.; Abrahamsson, J.; Griškevičius, L.; Hallböök, H.; Jónsson, G.; Palk, K.; Vaitkeviciene, G.; Vettenranta, K.; Åsberg, A.; Frandsen, T. L.; Opdahl, S.; Marquart, H. V.; Siitonen, S.; Osnes, L. T.; Hultdin, M.; Overgaard, U. M.; Wartiovaara-Kautto, U.; Schmiegelow, K.

In: Leukemia, Vol. 34, No. 2, 2020, p. 347-357.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Quist-Paulsen, P, Toft, N, Heyman, M, Abrahamsson, J, Griškevičius, L, Hallböök, H, Jónsson, G, Palk, K, Vaitkeviciene, G, Vettenranta, K, Åsberg, A, Frandsen, TL, Opdahl, S, Marquart, HV, Siitonen, S, Osnes, LT, Hultdin, M, Overgaard, UM, Wartiovaara-Kautto, U & Schmiegelow, K 2020, 'T-cell acute lymphoblastic leukemia in patients 1–45 years treated with the pediatric NOPHO ALL2008 protocol', Leukemia, vol. 34, no. 2, pp. 347-357. https://doi.org/10.1038/s41375-019-0598-2

APA

Quist-Paulsen, P., Toft, N., Heyman, M., Abrahamsson, J., Griškevičius, L., Hallböök, H., Jónsson, G., Palk, K., Vaitkeviciene, G., Vettenranta, K., Åsberg, A., Frandsen, T. L., Opdahl, S., Marquart, H. V., Siitonen, S., Osnes, L. T., Hultdin, M., Overgaard, U. M., Wartiovaara-Kautto, U., & Schmiegelow, K. (2020). T-cell acute lymphoblastic leukemia in patients 1–45 years treated with the pediatric NOPHO ALL2008 protocol. Leukemia, 34(2), 347-357. https://doi.org/10.1038/s41375-019-0598-2

Vancouver

Quist-Paulsen P, Toft N, Heyman M, Abrahamsson J, Griškevičius L, Hallböök H et al. T-cell acute lymphoblastic leukemia in patients 1–45 years treated with the pediatric NOPHO ALL2008 protocol. Leukemia. 2020;34(2):347-357. https://doi.org/10.1038/s41375-019-0598-2

Author

Quist-Paulsen, P. ; Toft, N. ; Heyman, M. ; Abrahamsson, J. ; Griškevičius, L. ; Hallböök, H. ; Jónsson, G. ; Palk, K. ; Vaitkeviciene, G. ; Vettenranta, K. ; Åsberg, A. ; Frandsen, T. L. ; Opdahl, S. ; Marquart, H. V. ; Siitonen, S. ; Osnes, L. T. ; Hultdin, M. ; Overgaard, U. M. ; Wartiovaara-Kautto, U. ; Schmiegelow, K. / T-cell acute lymphoblastic leukemia in patients 1–45 years treated with the pediatric NOPHO ALL2008 protocol. In: Leukemia. 2020 ; Vol. 34, No. 2. pp. 347-357.

Bibtex

@article{2ebaf7e6868d43aeb0974d6ad6b4b397,
title = "T-cell acute lymphoblastic leukemia in patients 1–45 years treated with the pediatric NOPHO ALL2008 protocol",
abstract = "The NOPHO ALL2008 is a population-based study using an unmodified pediatric protocol in patients 1–45 years of age with acute lymphoblastic leukemia. Patients with T-ALL were given a traditional pediatric scheme if fast responding (minimal residual disease (MRD) < 0.1% day 29), or intensive block-based chemotherapy if slow responding (MRD > 0.1% day 29). Both treatment arms included pediatric doses of high-dose methotrexate and asparaginase. If MRD ≥ 5% on day 29 or ≥0.1% after consolidation, patients were assigned to allogeneic hematopoietic stem cell transplantation. The 5-year overall survival of the 278 T-ALL patients was 0.75 (95% CI 0.69–0.81), being 0.82 (0.74–0.88) for patients 1.0–9.9 years, 0.76 (0.66–0.86) for those 10.0–17.9 years, and 0.65 (0.55–0.75) for the older patients. The risk of death in first remission was significantly higher in adults (12%) compared with the 1–9 years group (4%). The MRD responses in the three age groups were similar, and only a nonsignificant increase in relapse risk was found in adults. In conclusion, an unmodified pediatric protocol in patients 1–45 years is effective in all age groups. The traditional pediatric treatment schedule was safe for all patients, but the intensive block therapy led to a high toxic death rate in adults.",
author = "P. Quist-Paulsen and N. Toft and M. Heyman and J. Abrahamsson and L. Gri{\v s}kevi{\v c}ius and H. Hallb{\"o}{\"o}k and G. J{\'o}nsson and K. Palk and G. Vaitkeviciene and K. Vettenranta and A. {\AA}sberg and Frandsen, {T. L.} and S. Opdahl and Marquart, {H. V.} and S. Siitonen and Osnes, {L. T.} and M. Hultdin and Overgaard, {U. M.} and U. Wartiovaara-Kautto and K. Schmiegelow",
year = "2020",
doi = "10.1038/s41375-019-0598-2",
language = "English",
volume = "34",
pages = "347--357",
journal = "Leukemia",
issn = "0887-6924",
publisher = "nature publishing group",
number = "2",

}

RIS

TY - JOUR

T1 - T-cell acute lymphoblastic leukemia in patients 1–45 years treated with the pediatric NOPHO ALL2008 protocol

AU - Quist-Paulsen, P.

AU - Toft, N.

AU - Heyman, M.

AU - Abrahamsson, J.

AU - Griškevičius, L.

AU - Hallböök, H.

AU - Jónsson, G.

AU - Palk, K.

AU - Vaitkeviciene, G.

AU - Vettenranta, K.

AU - Åsberg, A.

AU - Frandsen, T. L.

AU - Opdahl, S.

AU - Marquart, H. V.

AU - Siitonen, S.

AU - Osnes, L. T.

AU - Hultdin, M.

AU - Overgaard, U. M.

AU - Wartiovaara-Kautto, U.

AU - Schmiegelow, K.

PY - 2020

Y1 - 2020

N2 - The NOPHO ALL2008 is a population-based study using an unmodified pediatric protocol in patients 1–45 years of age with acute lymphoblastic leukemia. Patients with T-ALL were given a traditional pediatric scheme if fast responding (minimal residual disease (MRD) < 0.1% day 29), or intensive block-based chemotherapy if slow responding (MRD > 0.1% day 29). Both treatment arms included pediatric doses of high-dose methotrexate and asparaginase. If MRD ≥ 5% on day 29 or ≥0.1% after consolidation, patients were assigned to allogeneic hematopoietic stem cell transplantation. The 5-year overall survival of the 278 T-ALL patients was 0.75 (95% CI 0.69–0.81), being 0.82 (0.74–0.88) for patients 1.0–9.9 years, 0.76 (0.66–0.86) for those 10.0–17.9 years, and 0.65 (0.55–0.75) for the older patients. The risk of death in first remission was significantly higher in adults (12%) compared with the 1–9 years group (4%). The MRD responses in the three age groups were similar, and only a nonsignificant increase in relapse risk was found in adults. In conclusion, an unmodified pediatric protocol in patients 1–45 years is effective in all age groups. The traditional pediatric treatment schedule was safe for all patients, but the intensive block therapy led to a high toxic death rate in adults.

AB - The NOPHO ALL2008 is a population-based study using an unmodified pediatric protocol in patients 1–45 years of age with acute lymphoblastic leukemia. Patients with T-ALL were given a traditional pediatric scheme if fast responding (minimal residual disease (MRD) < 0.1% day 29), or intensive block-based chemotherapy if slow responding (MRD > 0.1% day 29). Both treatment arms included pediatric doses of high-dose methotrexate and asparaginase. If MRD ≥ 5% on day 29 or ≥0.1% after consolidation, patients were assigned to allogeneic hematopoietic stem cell transplantation. The 5-year overall survival of the 278 T-ALL patients was 0.75 (95% CI 0.69–0.81), being 0.82 (0.74–0.88) for patients 1.0–9.9 years, 0.76 (0.66–0.86) for those 10.0–17.9 years, and 0.65 (0.55–0.75) for the older patients. The risk of death in first remission was significantly higher in adults (12%) compared with the 1–9 years group (4%). The MRD responses in the three age groups were similar, and only a nonsignificant increase in relapse risk was found in adults. In conclusion, an unmodified pediatric protocol in patients 1–45 years is effective in all age groups. The traditional pediatric treatment schedule was safe for all patients, but the intensive block therapy led to a high toxic death rate in adults.

U2 - 10.1038/s41375-019-0598-2

DO - 10.1038/s41375-019-0598-2

M3 - Journal article

C2 - 31611626

AN - SCOPUS:85076485737

VL - 34

SP - 347

EP - 357

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 2

ER -

ID: 236722616